mRNA-Based Therapeutics Summit on July 21-23, 2025 in Boston, United States

The mRNA field is on the cusp of revolutionary change, with cancer vaccines, in vivo cell engineering and gene editing technologies unleashing the next advancements of therapeutic candidates and developmental progress towards clinical and commercial approval.

To shine light on emerging areas and the latest progress, the 5th mRNA-Based Therapeutics Summit returns to Boston as the world's largest, end-to-end mRNA conference, gathering 350+ global stakeholders, sharing exclusive scientific and strategic insights from the biggest and newest players in the mRNA, Circular RNA and Self-Amplifying RNA fields including Moderna, Pfizer, BioNTech, Grann Pharmaceuticals, Celestial Therapeutics,Byterna Therapeutics and more.

Discover the realms of new infectious disease platforms, combating oncological targets and cell therapies across 4 dedicated tracks of content in Discovery, Pre-Clinical Development, Clinical Development and, Manufacturing and CMC as your one-stop-shop scientific content and partnering forum to aid the progress of pipelines in 2025 towards the clinic and ultimately patients in need.

URLs:

Tickets: https://go.evvnt.com/2922134-2?pid=10008

Brochure: https://go.evvnt.com/2922134-3?pid=10008

Prices:
Conference + Workshop Day OR Delivery Day - OTD - Drug Developer: USD 5446.00,
Conference + Workshop Day OR Delivery Day - OTD - Academic: USD 4746.00,
Conference + Workshop Day OR Delivery Day - OTD - Solution Provider: USD 6546.00,
Conference Only - OTD - Drug Developer: USD 3199.00,
Conference Only - OTD - Academic: USD 2799.00,
Conference Only - OTD - Solution Provider: USD 3999.00,
Add On Day Only - OTD - Drug Developer: USD 2347.00,
Add On Day Only - OTD - Academic: USD 2047.00,
Add On Day Only - OTD - Solution Provider: USD 2647.00

Speakers: Alexander Zehnder, Chief Executive Officer, CureVac, David Kolesky, Principal MPM, BioImpact, Ilya Vensky, General Partner, Provisio Ventures, Kristin Thompson, Investment Director, Merieux Equity Partners, Richard Shen, Managing Director, Sedgwick Yard, and Interim Chief Executive Officer, Endotope Biosciences, Thimmaiah Chendrimada, Founder, Able Sciences, Bo Ying, Chief Executive Officer, Abogen Biosciences, Manuel Vega, Chief Executive Officer, AGS Therapeutics, Daryl Drummond, Chief Scientific Officer, Akagera Medicines, Vincent Serra, Chief Scientific and Executive Officer, Amity Therapeutics (Neovacs), Robert Schwartz, Chief Scientific Officer, Animatus Biosciences, Joseph Payne, President and Chief Executive Officer, Arcturus Therapeutics, Amin Khan, Chief Scientific Advisor, Afrigen Biologics, Manmohan Singh, Chief Technology Officer, Beam Therapeutics, Xian Zeng, Co-Founder and Board Member, Byterna Therapeutics, Haig Aghajanian, Co-Founder and Vice President of Research, Capstan Therapeutics, Ajay Gupta, President, Chairman and Chief Executive Officer, Celestial Therapeutics, Thomas Langenickel, Chief Medical Officer, Ethris, Thomas Lyle-Temple, Chief Executive Officer, Grann Pharmaceuticals, Peter Bergland, Chief Scientific Officer, HDT Bio, Nicholas Valiante, Co-Founder and Chief Scientific Officer, Innovac Therapeutics, Zach Zhu, Chief Technology Officer, Innorna, Nicholas Restifo, Co-Founder and Chief Scientist, Medici Therapeutics, Randall Hyer, Chief Executive Officer, Merlin Biotech, Ron Philip, Chief Executive Officer, Orbital Therapeutics, Gilles Besin, Chief Scientific Officer, Orbital Therapeutics, Joe Bolen, Chief Scientific Officer, Orna Therapeutics, Soham Sankaran, Founder, Managing Director and Chief Executive Officer, PopVax, Natalia Martin-Orozco, Chief Scientific Officer, Providence Therapeutics, Sophia Lugo, Chief Executive Officer, Chairman and Co-Founder, Radar Therapeutics, Priya Mande, Chief Executive Officer, RNAvate, Nathaniel Wang, Chief Executive Officer, Replicate Bioscience, Trevor Hallam, Chief Scientific Officer, Sail Biomedicines, Abhinav Shukla, Chief Technology Officer,Shattuck Labs, William Ji, Chief Scientific Officer, Virogin Biotech, Xiangrong Song, Chief Executive Officer and Co-Founder, WestGene Biopharma, Bruce Turner, Founder, Chairman and Chief Executive Officer, Xanadu Bio, Jason Zhang, Co-Founder and Chief Executive Officer, ZipCode Bio, Beata Chertok, Team Lead – Delivery of Intracellular Biologics, AstraZeneca, George Thom, Director and mRNA Team Leader, AstraZeneca, Kinkini Roy, Associate Director – Drug Product Development, Aviceda Therapeutics, Andri Vasou, Head of Platform Development, Bioarchitech, Andreas Kuhn, Senior Vice President of RNA Biochemistry and CMC Development, BioNTech, Michelle Teplensky, Assistant Professor of Biomedical Engineering, Boston University and Scientific Founder, Flashpoint Therapeutics, Lingtao Peng, Director and Head of Molecular Cellular and Synthetic Biology, CSL, Chijian Zuo, Vice President, CureMed Biomedical Technology, Markus Bergmann, Global Program Head of Personalized Cancer Vaccines, CureVac, Sean Bedingfield, Senior Advisor – Genetic Medicine, Eli Lilly, Jaehyun Choi, Head of Research and Development and Executive Vice President, Genexine, Diana Posadas, Director of Strategic Research, GreenLight Biosciences, Jessica Kenison, Scientific Director, Immunocodex, Nikola Ivica, Head of Discovery, InnDura Therapeutics, Rachel Groppo, Director – Lead Self- Amplifying RNA Team, Johnson and Johnson, Joseph Parrella, Vice President of CMC, Kernal Bio, Alex Lagadinos, Head of Business Development, Mana Bio, Shyam Kumar, Gudey Principal Scientist, Moderna, Shefal Parikh, Senior Director of Drug Substance Development, nChromaBio, Mark Chipley, Principal Scientist, Pfizer, Edo Kon, Director of Business Development, RiboX Therapeutics, Dan Shores, Partner, Rothwell Figg, Ashoka Madduri, Global Head of Scientific Strategy and Intelligence, mRNA Centre of Excellence, Sanofi, Jianmei Kochling, Senior Director, Head of Analytical Development and Quality Control, mRNA Centre of Excellence, Sanofi, Allen Tseng, Principal Scientist – Synthetic Biology, Strand Therapeutics, Jaspreet Khurana, Senior Director of mRNA Programming, Strand Therapeutics, Ashish Kulkarni, Associate Professor of Chemical Engineering, University of Massachusetts Amherst, Hamideh Parhiz, Assistant Professor of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Kui Wang, Director, Verve Therapeutics

Time: 08:00 to 18:00